Niagen Bioscience cites preclinical study showing NR restores placental NAD+ and improves pregnancy outcomes in aged mice

• Niagen Bioscience highlighted an independent Nature Communications preclinical study on CD38-driven, age-related NAD+ decline in placental tissue.
• Human placental samples showed older mothers had lower NAD+, NADH, NADP+; higher metabolite levels correlated with higher infant birth weight.
• In aged pregnant mice, oral nicotinamide riboside or a CD38 inhibitor restored placental NAD+ and improved fetal growth outcomes.
• Mechanistic data showed CD38 degrades NMN outside cells; prior research cited NR as inhibiting CD38, supporting NR’s relative efficacy in high-CD38 tissue.
• Niagen Bioscience did not conduct, fund, or design the study; the NR used was not its Niagen ingredient.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609210832BIZWIRE_USPR_____20260921_BW027362) on September 21, 2026, and is solely responsible for the information contained therein.